NVCR · NovoCure Limited
$15.51
+1.04% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-18.8
Dividend yield
—
Beta
1.01
Avg volume
2M
Employees
2K
Daily Change %
1.04%
5 Days Change
-12.88%
10 Days Change
-11.44%
30 Days Change
-11.49%
60 Days Change
-4.11%
Month to Day Change
-10.07%
Year to Day Change
20.88%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NVCR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-24
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$17.00
+10.7% vs priceJP Morgan
Neutral$23.00
+49.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-24 | Wedbush | Maintains | Neutral | $18.00 → $20.00 |
| 2026-07-23 | HC Wainwright & Co. | Maintains | Buy | $46.00 → $52.00 |
| 2026-06-18 | HC Wainwright & Co. | Reiterates | Buy | $48.00 → $46.00 |
| 2026-05-04 | Wells Fargo | Maintains | Equal-Weight | $13.50 → $17.00 |
| 2026-05-01 | Evercore ISI Group | Maintains | Outperform | $16.00 → $20.00 |
| 2026-04-16 | Wedbush | Reiterates | Neutral | $18.00 |
| 2026-02-26 | HC Wainwright & Co. | Maintains | Buy | $47.00 → $49.00 |
| 2026-02-12 | HC Wainwright & Co. | Maintains | Buy | $39.00 → $47.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 39 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.8% below the 50-day MA ($16.83).
- Price vs 200-day MA: Trading 7.4% above the 200-day MA ($14.44).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.30) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($10.03) and high ($19.99).
NVCR Price Chart
Loading chart for NVCR…
Fundamentals
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
More in Medical Devices
ABT
Abbott Laboratories
$179B -14.4% YTD
MDT
Medtronic plc.
$117B -2.7% YTD
SYK
Stryker Corporation
$104B -21.2% YTD
BSX
Boston Scientific Corporation
$62B -52.8% YTD
EW
Edwards Lifesciences Corporatio
$50B 1.1% YTD
DXCM
DexCom, Inc.
$32B 26.4% YTD
GEHC
GE HealthCare Technologies Inc.
$29B -20.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.